Skip to main content
SpringerLink
Log in
Book cover

Clinical Strategies in the Management of Diabetic Retinopathy pp 163–178Cite as

Advanced Proliferative Diabetic Retinopathy

  • Chapter
  • First Online:

  • 1197 Accesses

Abstract

Advanced PDR is not only characterized by retinal neovascularization and vitreous hemorrhage (VH) but also can include rubeosis iridis, neovascular glaucoma, and development of preretinal fibrous membranes with tractional retinal detachment (TRD), macular dragging, and, sometimes, a combined traction-rhegmatogenous RD. Additional findings can include anterior hyaloidal fibrovascular proliferation, which can lead to cyclitic membrane formation, RD, and hypotony. Such eyes frequently undergo pars plana vitrectomy (PPV). In some cases, antiangiogenic adjuvant pharmacologic therapy is used to treat diabetes-related VH and neovascularization.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE (2008) The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 115:1859–1868

    Article  PubMed Central  PubMed  Google Scholar 

  2. Wong TY, Mwamburi M, Klein R et al (2009) Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 32:2307–2313

    Article  PubMed Central  PubMed  Google Scholar 

  3. Pugliese G, Solini A, Zoppini G, Renal Insufficiency and Cardiovascular Events (RIACE) Study Group et al (2012) High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Res Clin Pract 98(2):329–337

    Article  PubMed  Google Scholar 

  4. Fong DS, Ferris FL 3rd, Davis MD, Chew EY (1999) Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol 127:137–141

    Article  PubMed  CAS  Google Scholar 

  5. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO (2003) Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22:1–29

    Article  PubMed  CAS  Google Scholar 

  6. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487

    Article  PubMed  CAS  Google Scholar 

  7. Watanabe D, Suzuma K, Suzuma I et al (2005) Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 139:476–481

    Article  PubMed  CAS  Google Scholar 

  8. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232–1235

    Article  PubMed  CAS  Google Scholar 

  9. Qiu M, Xiong W, Liao H, Li F (2013) VEGF -634G>C polymorphism and diabetic retinopathy risk: a meta-analysis. Gene 518:310–315

    Article  PubMed  CAS  Google Scholar 

  10. Friedlander M (2007) Fibrosis and diseases of the eye. J Clin Invest 117:576–586

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Kawahara S, Hata Y, Kita T et al (2008) Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. Diabetes 57:2784–2793

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  12. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD et al (2008) The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS ONE 3:e2675

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  13. Tripathi RC, Li J, Tripathi BJ et al (1998) Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 105(2):232–237

    Article  PubMed  CAS  Google Scholar 

  14. Sone H, Okuda Y, Kawakami Y et al (1996) Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated (letter). Diabetes Care 19(11):1306–1307

    PubMed  CAS  Google Scholar 

  15. Aiello LM, Wand M, Liang G (1983) Neovascular glaucoma and vitreous hemorrhage following cataract surgery in patients with diabetes mellitus. Ophthalmology 90(7):814–820

    Article  PubMed  CAS  Google Scholar 

  16. Rice TA, Michels RG, Maguire MG, Rice EF (1983) The effect of lensectomy on the incidence of iris neovascularization and neovascular glaucoma after vitrectomy in diabetic retinopathy. Am J Ophthalmol 95:1–11

    PubMed  CAS  Google Scholar 

  17. Sanborn GE, Symes DJ, Margargal LE (1986) Fundus-iris fluorescein angiography: evaluation of its use in the diagnosis of rubeosis iridis. Ann Ophthalmol 18(2):52–58

    PubMed  CAS  Google Scholar 

  18. Lewis H, Abrams GW, Williams GA (1987) Anterior hyaloidal fibrovascular proliferation after diabetic vitrectomy. Am J Ophthalmol 104:607–613

    PubMed  CAS  Google Scholar 

  19. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings (1978) Ophthalmology 85:82–106

    Google Scholar 

  20. Photocoagulation in treatment of diabetic maculopathy. Interim report of a multicentre controlled study (1975) Lancet 2:1110–1113

    Google Scholar 

  21. Ferris F (1996) Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 94:505–537

    PubMed Central  PubMed  CAS  Google Scholar 

  22. McDonald HR, Schatz H (1985) Macular edema following panretinal photocoagulation. Retina 5:5–10

    Article  PubMed  CAS  Google Scholar 

  23. Lee SB, Yun YJ, Kim SH, Kim JY (2010) Changes in macular thickness after panretinal photocoagulation in patients with severe diabetic retinopathy and no macular edema. Retina 30:756–760

    Article  PubMed  Google Scholar 

  24. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M (2003) Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 110:2386–2394

    Article  PubMed  Google Scholar 

  25. Aiello LM (2003) Perspectives on diabetic retinopathy. Am J Ophthalmol 136:122–135

    Article  PubMed  Google Scholar 

  26. Unoki N, Nishijima K, Kita M et al (2009) Randomised controlled trial of posterior sub-Tenon triamcinolone as adjunct to panretinal photocoagulation for treatment of diabetic retinopathy. Br J Ophthalmol 93:765–770

    Article  PubMed  CAS  Google Scholar 

  27. Avery RL, Pearlman J, Pieramici DJ et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695.e1–1695.e15

    Google Scholar 

  28. Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M (2008) Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246:1699–1705

    Article  PubMed  CAS  Google Scholar 

  29. Arevalo JF, Maia M, Flynn HW Jr et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216

    Article  PubMed  CAS  Google Scholar 

  30. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5 (1990) Arch Ophthalmol 108:958–964

    Google Scholar 

  31. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial – Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group (1988) Ophthalmology 95:1307–1320

    Google Scholar 

  32. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial – Diabetic Retinopathy Vitrectomy Study Report 4. The Diabetic Retinopathy Vitrectomy Study Research Group (1988) Ophthalmology 95:1321–1334.

    Google Scholar 

  33. Charles S, Flinn CE (1981) The natural history of diabetic extramacular traction retinal detachment. Arch Ophthalmol 99:66–68

    Article  PubMed  CAS  Google Scholar 

  34. Yorston D, Wickham L, Benson S, Bunce C, Sheard R, Charteris D (2008) Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol 92:365–368

    Article  PubMed  CAS  Google Scholar 

  35. Stalmans P, Benz MS, Gandorfer A et al (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:606–615

    Article  PubMed  CAS  Google Scholar 

  36. Altaweel MM, Macugen Diabetic Retinopathy Study Group (2006) Changes in severity of diabetic retinopathy following pegaptanib (Macugen®) therapy. Poster presented at: annual meeting of Association for Research in Vision and Ophthalmology, Fort Lauderdale, 11 April 2006

    Google Scholar 

  37. Gonzalez VH, Vann, Banda RM, Guel DA, and Macugen (2006) Use of pegaptanib sodium (Macugen®) for the regression of proliferative diabetic retinopathy. Poster session presented at: annual meeting of Association for Research in Vision and Ophthalmology, Fort Lauderdale, 1 May 2006

    Google Scholar 

  38. Oshima Y, Sakaguchi H, Gomi F, Tano Y (2006) Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142:155–158

    Article  PubMed  CAS  Google Scholar 

  39. Isaacs TW, Barry C (2006) Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 34:802–803

    Article  PubMed  Google Scholar 

  40. Tu Y, Fay C, Guo S, Zarbin MA, Marcus E, Bhagat N (2012) Ranibizumab in patients with dense cataract and proliferative diabetic retinopathy with rubeosis. Oman J Ophthalmol 5:161–165

    Article  PubMed Central  PubMed  Google Scholar 

  41. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H (2008) Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 18:263–269

    PubMed  CAS  Google Scholar 

  42. Cho WB, Oh SB, Moon JW, Kim HC (2009) Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 29:516–522

    Article  PubMed  Google Scholar 

  43. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G (2008) Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 246:837–842

    Article  PubMed  CAS  Google Scholar 

  44. Marcus E, Zarbin MA, Fay C, Bhagat N. Rubeosis study: a pilot study to evaluate the safety and efficacy of Lucentis in Diabetic Eyes with rubeosis and advanced cataract. Poster session presented at: annual meeting of Association for Research in Vision and Ophthalmology, Fort Lauderdale, 11 Apr 2010

    Google Scholar 

  45. Kahook MY, Schuman JS, Noecker RJ (2006) Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 37:144–146

    PubMed  Google Scholar 

  46. Mason JO 3rd, Yunker JJ, Vail R, McGwin G Jr (2008) Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina 28:1319–1324

    Article  PubMed  Google Scholar 

  47. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278

    Article  PubMed  Google Scholar 

  48. Diabetic Retinopathy Clinical Research Network (2013) Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 131:283–293

    Article  CAS  Google Scholar 

  49. Yeung L, Liu L, Wu WC et al (2010) Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment. Acta Ophthalmol 88:635–640

    Article  PubMed  CAS  Google Scholar 

  50. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R (2009) Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 116:1943–1948

    Article  PubMed  Google Scholar 

  51. Chen E, Park CH (2006) Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26:699–700

    Article  PubMed  Google Scholar 

  52. Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM (2009) Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 29:1134–1140

    Article  PubMed  Google Scholar 

  53. Zhao LQ, Zhu H, Zhao PQ, Hu YQ (2011) A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 95:1216–1222

    Article  PubMed Central  PubMed  Google Scholar 

  54. Ribeiro JA, Messias A, de Almeida FP et al (2011) The effect of intravitreal ranibizumab on intraoperative bleeding during pars plana vitrectomy for diabetic traction retinal detachment. Br J Ophthalmol 95:1337–1339

    Article  PubMed  Google Scholar 

  55. Ishikawa K, Honda S, Tsukahara Y, Negi A (2009) Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond) 23:108–111

    Article  CAS  Google Scholar 

  56. Kohno R, Hata Y, Mochizuki Y et al (2010) Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol 150:223–229.e1

    Article  PubMed  CAS  Google Scholar 

  57. El-Sabagh HA, Abdelghaffar W, Labib AM et al (2011) Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology 118:636–641

    Article  PubMed  Google Scholar 

  58. Heiduschka P, Fietz H, Hofmeister S et al (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48:2814–2823

    Article  PubMed  Google Scholar 

  59. Falavarjani K, Modarres M, Nazari H (2010) Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye 24(4):717–719

    Article  PubMed  CAS  Google Scholar 

  60. Han DP, Lewandowski M, Mieler WF (1991) Echographic diagnosis of anterior hyaloidal fibrovascular proliferation. Arch Ophthalmol 109:842–846

    Article  PubMed  CAS  Google Scholar 

  61. Schepens CL (1981) Clinical and research aspects of subtotal open-sky vitrectomy. XXXVII Edward Jackson Memorial Lecture. Am J Ophthalmol 91:143–171

    PubMed  CAS  Google Scholar 

  62. Lean JS, Leaver PK, Cooling RJ, McLeod D (1982) Management of complex retinal detachments by vitrectomy and fluid/silicone exchange. Trans Ophthalmol Soc U K 102(Pt 1):203–205

    PubMed  Google Scholar 

  63. McLeod D (1986) Silicone-oil injection during closed microsurgery for diabetic retinal detachment. Graefes Arch Clin Exp Ophthalmol 224:55–59

    Article  PubMed  CAS  Google Scholar 

  64. de Corral LR, Peyman GA (1986) Pars plana vitrectomy and intravitreal silicone oil injection in eyes with rubeosis iridis. Can J Ophthalmol 21:10–12

    Google Scholar 

  65. Yeo JH, Glaser BM, Michels RG (1987) Silicone oil in the treatment of complicated retinal detachments. Ophthalmology 94:1109–1113

    Article  PubMed  CAS  Google Scholar 

  66. Lucke KH, Foerster MH, Laqua H (1987) Long-term results of vitrectomy and silicone oil in 500 cases of complicated retinal detachments. Am J Ophthalmol 104:624–633

    PubMed  CAS  Google Scholar 

  67. Heimann K, Dahl B, Dimopoulos S, Lemmen KD (1989) Pars plana vitrectomy and silicone oil injection in proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 227:152–156

    Article  PubMed  CAS  Google Scholar 

  68. Brourman ND, Blumenkranz MS, Cox MS, Trese MT (1989) Silicone oil for the treatment of severe proliferative diabetic retinopathy. Ophthalmology 96:759–764

    Article  PubMed  CAS  Google Scholar 

  69. McCuen BW 2nd, Rinkoff JS (1989) Silicone oil for progressive anterior ocular neovascularization after failed diabetic vitrectomy. Arch Ophthalmol 107:677–682

    Article  PubMed  Google Scholar 

  70. Gonvers M (1990) Temporary silicone oil tamponade in the treatment of complicated diabetic retinal detachments. Graefes Arch Clin Exp Ophthalmol 228:415–422

    Article  PubMed  CAS  Google Scholar 

  71. Riedel KG, Gabel VP, Neubauer L, Kampik A, Lund OE (1990) Intravitreal silicone oil injection: complications and treatment of 415 consecutive patients. Graefes Arch Clin Exp Ophthalmol 228:19–23

    Article  PubMed  CAS  Google Scholar 

  72. Karel I, Kalvodova B (1994) Long-term results of pars plana vitrectomy and silicone oil for complications of diabetic retinopathy. Eur J Ophthalmol 4:52–58

    PubMed  CAS  Google Scholar 

  73. Fisk MJ, Cairns JD (1995) Silicone oil insertion. A review of 127 consecutive cases. Aust N Z J Ophthalmol 23:25–32

    Article  PubMed  CAS  Google Scholar 

  74. Azen SP, Scott IU, Flynn HW Jr et al (1998) Silicone oil in the repair of complex retinal detachments. A prospective observational multicenter study. Ophthalmology 105:1587–1597

    Article  PubMed  CAS  Google Scholar 

  75. Scott IU, Flynn HW, Lai M, Chang S, Azen SP (2000) First operation anatomic success and other predictors of postoperative vision after complex retinal detachment repair with vitrectomy and silicone oil tamponade. Am J Ophthalmol 130:745–750

    Article  PubMed  CAS  Google Scholar 

  76. Castellarin A, Grigorian R, Bhagat N, Del Priore L, Zarbin MA (2003) Vitrectomy with silicone oil infusion in severe diabetic retinopathy. Br J Ophthalmol 87:318–321

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  77. Grigorian RA, Castellarin A, Bhagat N, Del Priore L, Von Hagen S, Zarbin MA (2003) Use of viscodissection and silicone oil in vitrectomy for severe diabetic retinopathy. Semin Ophthalmol 18:121–126

    Article  PubMed  CAS  Google Scholar 

  78. Charles S (1987) Vitreous surgery, 2nd edn. Williams and Wilkins, Baltimore

    Google Scholar 

  79. de Juan E Jr, Hardy M, Hatchell DL, Hatchell MC (1986) The effect of intraocular silicone oil on anterior chamber oxygen pressure in cats. Arch Ophthalmol 104:1063–1064

    Article  PubMed  Google Scholar 

  80. Rinkoff JS, de Juan E Jr, McCuen BW 2nd (1986) Silicone oil for retinal detachment with advanced proliferative vitreoretinopathy following failed vitrectomy for proliferative diabetic retinopathy. Am J Ophthalmol 101:181–186

    PubMed  CAS  Google Scholar 

  81. Glaser BM, D’Amore PA, Michels RG, Patz A, Fenselau A (1980) Demonstration of vasoproliferative activity from mammalian retina. J Cell Biol 84:298–304

    Article  PubMed  CAS  Google Scholar 

  82. Kolomeyer AM, Grigorian RA, Mostafavi D, Bhagat N, Zarbin MA (2011) 360 degrees retinectomy for the treatment of complex retinal detachment. Retina 31:266–274

    Article  PubMed  Google Scholar 

  83. Stenkula S, Ivert L, Gislason I, Tornquist R, Weijdegard L (1981) The use of sodium-hyaluronate (Healon) in the treatment of retinal detachment. Ophthalmic Surg 12:435–437

    PubMed  CAS  Google Scholar 

  84. McLeod D, James CR (1988) Viscodelamination at the vitreoretinal juncture in severe diabetic eye disease. Br J Ophthalmol 72:413–419

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  85. Crafoord S, Stenkula S (1993) Healon GV in posterior segment surgery. Acta Ophthalmol (Copenh) 71:560–561

    Article  CAS  Google Scholar 

  86. Grigorian RA, Castellarin A, Fegan R et al (2003) Epiretinal membrane removal in diabetic eyes: comparison of viscodissection with conventional methods of membrane peeling. Br J Ophthalmol 87:737–741

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Ophthalmology and Visual Science, New Jersey Medical School, Rutgers University, Room 6156, Doctors Office Center Suite 6100, 90 Bergen Street, Newark, NJ, 07103, USA

    Neelakshi Bhagat MD, MPH, FACS & Marco Attilo Zarbin MD, PhD

  2. Department of Ophthalmology, University Hospital, Room 6156, Doctors Office Center, 90 Bergen Street, Newark, NJ, 07103, USA

    Marco Attilo Zarbin MD, PhD

Authors
  1. Neelakshi Bhagat MD, MPH, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Attilo Zarbin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Attilo Zarbin MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, University Vita-Salute Scientific Institute San Raffaele, Milano, Italy

    Francesco Bandello

  2. Department of Ophthalmology, Rutgers University, Newark, New Jersey, USA

    Marco Attilio Zarbin

  3. Department of Ophthalmology, University Vita-Salute Scientific Institute San Raffaele, Milan, Italy

    Rosangela Lattanzio

  4. Department of Ophthalmology, University Vita-Salute Scientific Institute San Raffaele, Milan, Italy

    Ilaria Zucchiatti

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bhagat, N., Zarbin, M.A. (2014). Advanced Proliferative Diabetic Retinopathy. In: Bandello, F., Zarbin, M., Lattanzio, R., Zucchiatti, I. (eds) Clinical Strategies in the Management of Diabetic Retinopathy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54503-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54503-0_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54502-3

  • Online ISBN: 978-3-642-54503-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation